Skip to content


  • Poster presentation
  • Open Access

P87 - A national multicenter registration of treatment with omalizumab in Danish asthmatic children

  • 1,
  • 1,
  • 1,
  • 1,
  • 1,
  • 1,
  • 1,
  • 1,
  • 1 and
  • 1
Clinical and Translational Allergy20144 (Suppl 1) :P142

  • Published:


  • Asthma
  • Rhinitis
  • Asthmatic Child
  • Allergic Asthma
  • Asthma Exacerbation


In Denmark, Omalizumab is approved for treating children with severe persistent allergic asthma older than 6 years of age. No systematic registration of the efficacy in the Danish child population according to asthma symptoms or the efficacy on co-morbid allergic symptoms exists. A broad panel of outcome measures is necessary to evaluate the efficacy of Omalizumab treatment.


To provide a standardized systematic registration in order to create a database enrolling children with severe allergic asthma treated with Omalizumab.

Method and study design

A national multicenter registration and follow-up study based on children with clinical persistent severe allergic asthma including both retrospective and prospective registration.

Inclusion criteria

Children, 6-18 years of age, with severe persistent allergic asthma according to GINA treated with Omalizumab.

Outcome registration

A broad panel of outcome measures is scheduled at baseline and during treatment:


  • Asthma exacerbations

  • Hospitalizations

  • Medication

  • Lung function

  • ACT score

  • Peak-flow

  • FeNO

  • Mannitol/Methacholin test

  • Skin prick-test

  • Quality of life score. (Juniper)

  • Rhinitis score, R-RTSS

  • SCORAD score

The monitoring plan and follow-up programme will be presented in a flowchart.


We believe that a national systematic registration will increase knowledge regarding efficacy of Omalizumab treatment in this rare group of severe allergic asthmatic children.

Authors’ Affiliations

Pediatric Department, Hillerød University Hospital, Denmark